A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile

What is the purpose of this trial?

This is a multicenter, randomized, double-blind study being conducted as a postmarketing requirement to the US Food and Drug Administration (FDA) to evaluate whether there is a lower starting dosage of lenvatinib 24 mg once daily (QD) that provides comparable efficacy but has a better safety profile in participants with radioiodine-refractory differentiated thyroid cancer RR-DTC with radiographic evidence of disease progression within the prior 12 months.

Participation Guidelines

Ages: 18 years and older

Gender: Both

Eisai Pharmaceuticals

Start Date: 01/30/2019

End Date: 10/30/2020

Last Updated: 01/31/2019

Study HIC#: 2000022491

Get Involved

For more information about this study, contact:
Matthew Piscatelli
+1 203-737-8367


Hari Deshpande

Principal Investigator